Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2014 4
2015 2
2016 1
2017 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Fibroblast Growth Factor Family in the Progression of Prostate Cancer.
Teishima J, Hayashi T, Nagamatsu H, Shoji K, Shikuma H, Yamanaka R, Sekino Y, Goto K, Inoue S, Matsubara A. Teishima J, et al. Among authors: shoji k. J Clin Med. 2019 Feb 4;8(2):183. doi: 10.3390/jcm8020183. J Clin Med. 2019. PMID: 30720727 Free PMC article. Review.
FGF19 promotes progression of prostate cancer.
Nagamatsu H, Teishima J, Goto K, Shikuma H, Kitano H, Shoji K, Inoue S, Matsubara A. Nagamatsu H, et al. Among authors: shoji k. Prostate. 2015 Jul 1;75(10):1092-101. doi: 10.1002/pros.22994. Epub 2015 Apr 8. Prostate. 2015. PMID: 25854696
The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients.
Kobayashi K, Yamamoto S, Takahashi S, Ishikawa K, Yasuda M, Wada K, Hamasuna R, Hayami H, Minamitani S, Matsumoto T, Kiyota H, Tateda K, Sato J, Hanaki H, Masumori N, Hiyama Y, Yamada H, Egawa S, Kimura T, Nishiyama H, Miyazaki J, Matsumoto K, Homma Y, Kamei J, Fujimoto K, Torimoto K, Tanaka K, Togo Y, Uehara S, Matsubara A, Shoji K, Goto H, Komeda H, Ito T, Mori K, Mita K, Kato M, Fujimoto Y, Masue T, Inatomi H, Takahashi Y, Ishihara S, Nishimura K, Mitsumori K, Ito N, Kanamaru S, Yamada D, Hiroshi M, Yamashita M, Tsugawa M, Takenaka T, Takahashi K, Oka Y, Yasufuku T, Watanabe S, Chihara Y, Okumura K, Kawanishi H, Matsukawa M, Shigeta M, Koda S. Kobayashi K, et al. Among authors: shoji k. J Infect Chemother. 2020 May;26(5):418-428. doi: 10.1016/j.jiac.2020.01.004. Epub 2020 Feb 17. J Infect Chemother. 2020. PMID: 32081647
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy.
Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, Kobayashi K, Ohara S, Kajiwara M, Matsubara A. Teishima J, et al. Among authors: shoji k. Oncol Lett. 2014 Aug;8(2):881-885. doi: 10.3892/ol.2014.2207. Epub 2014 Jun 2. Oncol Lett. 2014. PMID: 25013512 Free PMC article.
The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.
Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, Shinmei S, Shoji K, Inoue S, Hayashi T, Inoue Y, Ohara S, Mita K, Matsubara A. Teishima J, et al. Among authors: shoji k. BJU Int. 2016 Jun;117(6B):E67-74. doi: 10.1111/bju.13260. Epub 2015 Sep 25. BJU Int. 2016. PMID: 26305535
14 results